Notice: This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CYTX vs. RGLS, AGEN, FBIO, CRIS, SABS, BOLT, MTEM, AMGN, VRTX, and GILDShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Regulus Therapeutics Agenus Fortress Biotech Curis SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Cytori Therapeutics (NASDAQ:CYTX) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders have more ownership in CYTX or RGLS? 2.6% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 0.7% of Cytori Therapeutics shares are held by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable valuation and earnings, CYTX or RGLS? Cytori Therapeutics has higher revenue and earnings than Regulus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M7.13-$12.63MN/AN/ARegulus TherapeuticsN/AN/A-$30.04M-$1.07-1.37 Do analysts rate CYTX or RGLS? Regulus Therapeutics has a consensus price target of $10.80, indicating a potential upside of 634.69%. Given Regulus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Regulus Therapeutics is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media favor CYTX or RGLS? In the previous week, Regulus Therapeutics had 2 more articles in the media than Cytori Therapeutics. MarketBeat recorded 2 mentions for Regulus Therapeutics and 0 mentions for Cytori Therapeutics. Cytori Therapeutics' average media sentiment score of 0.00 beat Regulus Therapeutics' score of -0.06 indicating that Cytori Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cytori Therapeutics Neutral Regulus Therapeutics Neutral Does the MarketBeat Community believe in CYTX or RGLS? Regulus Therapeutics received 48 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformCytori TherapeuticsOutperform Votes44273.67% Underperform Votes15826.33% Regulus TherapeuticsOutperform Votes49063.80% Underperform Votes27836.20% Is CYTX or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. Regulus Therapeutics' return on equity of -53.07% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% Regulus Therapeutics N/A -53.07%-48.58% Which has more volatility and risk, CYTX or RGLS? Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. SummaryRegulus Therapeutics beats Cytori Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.15M$4.49B$5.22B$8.83BDividend YieldN/A45.94%5.53%4.08%P/E RatioN/A24.9792.5417.53Price / Sales7.1344.691,233.8096.02Price / CashN/A55.6541.4336.94Price / Book3.375.987.236.54Net Income-$12.63M$13.99M$119.89M$226.07M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$1.18-1.7%N/A-34.4%$26.15M$3.67M0.0037RGLSRegulus Therapeutics2.5241 of 5 stars$1.47+5.0%$10.80+634.7%+13.1%$96.29MN/A-1.3730News CoverageGap UpAGENAgenus3.8912 of 5 stars$3.34+16.8%$10.00+199.4%-75.4%$78.36M$156.31M0.00389Analyst RevisionGap DownFBIOFortress Biotech3.0726 of 5 stars$1.61+2.5%$13.67+748.9%-26.8%$44.44M$84.51M0.00186Analyst RevisionCRISCuris2.1589 of 5 stars$4.03-1.7%$23.00+470.7%-51.9%$34.13M$10.02M-0.5249SABSSAB Biotherapeutics3.1617 of 5 stars$3.13+2.0%$12.40+296.2%+233.0%$28.89M$2.24M0.00140Gap UpBOLTBolt Biotherapeutics3.4181 of 5 stars$0.58+1.8%$3.50+504.9%-35.6%$22.14M$7.88M0.00100MTEMMolecular Templates2.2638 of 5 stars$0.34-10.7%N/A-93.1%$2.21M$57.31M0.0062News CoverageGap UpAMGNAmgen4.9287 of 5 stars$294.53+1.6%$333.57+13.3%+11.3%$158.32B$28.19B37.7126,700Analyst RevisionNews CoveragePositive NewsVRTXVertex Pharmaceuticals4.0619 of 5 stars$450.97+0.1%$504.38+11.8%+27.7%$116.14B$9.87B0.005,400Analyst DowngradeAnalyst RevisionNews CoveragePositive NewsGILDGilead Sciences4.5151 of 5 stars$90.19+0.5%$95.41+5.8%+19.1%$112.40B$27.12B1,002.1118,000Analyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies RGLS Competitors AGEN Competitors FBIO Competitors CRIS Competitors SABS Competitors BOLT Competitors MTEM Competitors AMGN Competitors VRTX Competitors GILD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredReality Check: Are You Prepared for What's Next?Global shifts, like the alliance of BRICS nations pushing for economic independence from the U.S. dollar, and ...Allegiance Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
